Metagenomi, Inc..
MGX.US | Research and experimental development on natural sciences and engineering
Metagenomi, Inc. is a biopharmaceutical company focused on discovering and developing novel therapeutics using metagenomics. They leverage a proprietary platform to identify and engineer novel enzymes and other biological molecules from environmental DNA. These discoveries are then applied to develo...Show More
Better Health for All
0
No evidence available to assess Metagenomi, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Metagenomi, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
Metagenomi's employees rate the company 4.1 out of 5 stars, which translates to an 82% engagement score.
1
This rating is in line with the average for employers within the Pharmaceutical & Biotechnology industry.
2
Additionally, 72% of employees would recommend working at Metagenomi, and 81% approve of the CEO.
3
Fair Trade & Ethical Sourcing
0
No information or specific data points were found in the provided articles regarding Metagenomi, Inc.'s performance on any of the KPIs related to Fair Trade & Ethical Sourcing.
1
The articles explicitly state that there is no mention of fair trade, ethical sourcing, or related metrics such as certifications, audits, labour incidents, traceability, remediation, ethical clauses, high-risk materials, or supplier diversity spend.
2
Honest & Fair Business
0
Metagenomi, Inc. is currently under investigation by The Schall Law Firm for potential securities law violations, specifically concerning possible false or misleading statements or omissions of material information related to its Initial Public Offering (IPO) on February 12, 2024.
1
This investigation was triggered by the company's announcement of the termination of its collaboration with Moderna less than two months after the IPO.
2
Additionally, the company faces a class-action lawsuit alleging misrepresentations in its 2024 IPO, specifically regarding the failure to disclose material information about the risk of the Moderna collaboration's termination.
3
A review of director independence was conducted in 2023, and FCPA compliance is mentioned.
4
No specific data points were found for regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policy strength, or third-party verification of ethical claims.
5
Kind to Animals
0
No evidence available to assess Metagenomi, Inc. on Kind to Animals.
No War, No Weapons
0
The provided articles discuss the general concept of dual-use technologies, particularly in biotechnology and gene editing, and the potential for misuse. However, none of the articles offer specific, concrete evidence linking Metagenomi, Inc. (MGX.US) to any arms manufacturing, military contracts, dual-use technology development with military applications, sales to embargoed regimes, or any other activities relevant to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the available information.
Planet-Friendly Business
0
No evidence available to assess Metagenomi, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific data or evidence regarding Metagenomi, Inc.'s respect for cultures and communities, or any related KPIs, was found in the provided articles.
1
Safe & Smart Tech
0
No evidence available to assess Metagenomi, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific details regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles.
1